493
Participants
Start Date
October 31, 2014
Primary Completion Date
August 31, 2016
Study Completion Date
January 31, 2021
ONO-4538
Placebo
Taipei Clinical Site, Taipei
Taipei Clinical Site, Taipei
Taipei Clinical Site, Taipei
Taoyuan Clinical Site, Taoyuan District
Tainan Clinical Site, Tainan City
Kaohsiung Clinical Site, Kaohsiung City
Kaohsiung Clinical Site, Kaohsiung City
Taipei Clinical Site, Taipei
Taichung Clinical Site, Taichung
Aichi Clinical Site, Nagoya
Aomori Clinical Site, Misawa
Ehime Clinical Site, Matsuyama
Hokkaido Clinical Site, Sapporo
Hyogo Clinical Site, Akashi
Hyogo Clinical Site, Kobe
Ishikawa Clinical Site, Kanazawa
Kanagawa Clinical Site, Kawasaki
Kanagawa Clinical Site, Sagamihara
Kanagawa Clinical Site, Yokohama
Nagano Clinical Site, Saku
Osaka Clinical Site, Sayama
Osaka Clinical Site, Suita
Osaka Clinical Site, Takatsuki
Saitama Clinical Site, Kitaadachi
Shizuoka Clinical Site, Sunto-gun
Tochigi Clinical Site, Shimotsuke
Tokyo Clinical Site, Bunkyo-ku
Tokyo Clinical Site, Chuo-ku
Tokyo Clinical Site, Koto-ku
Tokyo Clinical Site, Shinjuku-ku
Chiba Clinical Site, Chiba
Fukuoka Clinical Site, Fukuoka
Fukuoka Clinical Site, Fukuoka
Gifu Clinical Site, Gifu
Hiroshima Clinical Site, Hiroshima
Osaka Clinical Site, Osaka
Shizuoka Clinical Site, Shizuoka
Busan-si Clinical Site, Busan
Daegu Clinical Site, Daegu
Gyeonggi-Do Clinical Site, Gyeonggi-do
Gyeonggi-Do Clinical Site, Gyeonggi-do
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Lead Sponsor
Ono Pharmaceutical Co. Ltd
INDUSTRY